Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
暂无分享,去创建一个
J. Gajewski | L. Valiquette | S. Herschorn | J. Corcos | S. Radomski | K. Ethans | L. Carr | K. Carlson | G. Bailly | R. Baverstock | R. Bard
[1] J. Pannek,et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany , 2010, World Journal of Urology.
[2] G. Kramer,et al. Treatment of Neurogenic Detrusor Overactivity with Botulinum Toxin A: The First Seven Years , 2009, Urologia Internationalis.
[3] V. Forin,et al. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. , 2009, Journal of pediatric urology.
[4] N. Őzgirgin,et al. Urinary dysfunction in multiple sclerosis , 2009, Journal of Clinical Neuroscience.
[5] J. Pannek,et al. EAU guidelines on neurogenic lower urinary tract dysfunction. , 2009, European urology.
[6] B. Schurch,et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. , 2007, European urology.
[7] B. Schurch,et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. , 2007, Archives of physical medicine and rehabilitation.
[8] L. Brundin,et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity , 2007, Scandinavian journal of urology and nephrology.
[9] T. Riise,et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis , 2007, Multiple sclerosis.
[10] K R Abrams,et al. Systematic review and evaluation of methods of assessing urinary incontinence. , 2006, Health technology assessment.
[11] W. Kitisomprayoonkul,et al. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. , 2005, Archives of physical medicine and rehabilitation.
[12] P. Dasgupta,et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. , 2005, The Journal of urology.
[13] T. Kessler,et al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? , 2005, Neurourology and urodynamics.
[14] J. Cadoret,et al. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. , 2005, The Canadian journal of urology.
[15] V. Bini,et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. , 2004, The Journal of urology.
[16] Emmanuel Chartier-Kastler,et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. , 2004, European urology.
[17] P. Navarra,et al. New therapeutic options for refractory neurogenic detrusor overactivity. , 2004, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[18] K. Andersson. Antimuscarinics for treatment of overactive bladder , 2004, The Lancet Neurology.
[19] B. Schurch,et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. , 2000, The Journal of urology.
[20] N. Resnick,et al. Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. , 2000, The Journal of urology.
[21] A. Jackson,et al. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. , 1999, Archives of physical medicine and rehabilitation.
[22] R. Swingler,et al. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis , 1999, Journal of Neurology.
[23] D L Patrick,et al. Quality of life of persons with urinary incontinence: development of a new measure. , 1998, Urology.
[24] F. Biering-Sørensen,et al. Urinary incontinence in spinal cord injured individuals 10–45 years after injury , 2010, Spinal Cord.
[25] M. Brin,et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. , 2005, The Journal of urology.
[26] J. Donovan,et al. ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence , 2004, Neurourology and urodynamics.
[27] M. Fall,et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. , 2002, American journal of obstetrics and gynecology.
[28] A. Rossier,et al. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures , 1999, Neurourology and urodynamics.
[29] A. Victor,et al. Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction , 1998, Neurourology and urodynamics.
[30] J. Donovan,et al. Outcome measures for research in treatment of adult males with symptoms of lower urinary tract dysfunction , 1998, Neurourology and urodynamics.